Form 4: Silexion Therapeutics Officer Receives RSUs

Hadar Mirit Horenshtein, CFO and Secretary of Silexion Therapeutics Corp, was granted 7,500 ordinary shares via fully vested restricted stock units.

Summary

• Hadar Mirit Horenshtein, the Chief Financial Officer and Secretary of Silexion Therapeutics Corp, received a grant of 7,500 ordinary shares.
• These shares were settled from fully vested restricted stock units (RSUs) awarded for services rendered as an officer.
• The grant was approved by the Issuer's board of directors.
• The reported shares reflect an adjustment due to a 1-for-10 reverse share split effective May 28, 2026.
• Prior to this grant, the reporting person owned 5,015 ordinary shares post-reverse split.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a standard executive compensation transaction rather than a significant financial event or strategic shift for the company.

Positives

• Grant of restricted stock units to a key executive, indicating continued investment in and retention of management talent.
• The RSUs were fully vested and immediately settled, providing direct ownership of shares.
• The transaction was approved by the board of directors, suggesting proper corporate governance oversight.

Future Outlook

No specific future outlook or guidance is provided in this filing, as it pertains to an insider stock transaction.

Industry Context

StockSavvy.ai notes that the issuance of RSUs to executives is a common practice in the biotechnology and pharmaceutical sectors, like Silexion Therapeutics, to align executive interests with shareholder value and attract/retain talent in a competitive industry.

Stakeholder Impact

• Shareholders: The grant of shares to management is a standard form of compensation and does not immediately impact shareholder value, though it dilutes existing ownership slightly. The reverse stock split, however, may affect perception and trading dynamics.
• Employees: The RSU grant is specific to the CFO and Secretary and does not directly impact other employees.
• Management: The grant serves as a form of incentive and compensation for the CFO and Secretary.

Key Dates

Keywords

Silexion Therapeutics Corp, SLXN, Form 4, Insider Transaction, Restricted Stock Units, RSU Grant, CFO, Secretary, Executive Compensation, Shareholder Equity